der Kogel AJ, Oyen WJ, et al: Correlation of [18F]FMISO autoradiography and pimonidazole (corrected) immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008;35:1803–1811.
35Troost EG, Bussink J, Kaanders JH, van Eerd J, Peters JP, Rijken PF, et al: Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 2005;76:194–199.
36Shi K, Bayer C, Astner ST, Gaertner FC, Vaupel P, Schwaiger M, et al: Quantitative analysis of [18F]FMISO PET for tumor hypoxia: correlation of modeling results with immunohistochemistry. Mol Imaging Biol 2017;19:120–129.
37van Elmpt W, Zegers CM, Reymen B, Even AJ, Dingemans AM, Oellers M, et al: Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. Eur J Nucl Med Mol Imaging 2016;43:240–248.
38Taylor E, Yeung I, Keller H, Wouters BG, Milosevic M, Hedley DW, et al: Quantifying hypoxia in human cancers using static PET imaging. Phys Med Biol 2016;61:7957–7974.
39Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts SA: A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med 2014;55:515–521.
40O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al: Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493–1502.
41Ljungkvist AS, Bussink J, Kaanders JH, Rijken PF, Begg AC, Raleigh JA, et al: Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 2005;62:1157–1168.
42Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ: Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 2007;167:127–145.
43Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, van der Kogel AJ: Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 2000;48:1529–1538.
44Price JM, Robinson SP, Koh DM: Imaging hypoxia in tumours with advanced MRI. Q J Nucl Med Mol Imaging 2013;57:257–270.
45King AD, Thoeny HC: Functional MRI for the prediction of treatment response in head and neck squamous cell carcinoma: potential and limitations. Cancer Imaging 2016;16:23.
46Begg AC, Haustermans K, Hart AA, Dische S, Saunders M, Zackrisson B, et al: The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 1999;50:13–23.
47Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, et al: Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck 2015;37:763–770.
48Wang JZ, Li XA: Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys 2005;61:220–227.
49Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH: 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 2010;51:866–874.
50Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311–322.
51Soloviev D, Lewis D, Honess D, Aboagye E: [18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 2012;48:416–424.
52Debebe SA, Goryawala M, Adjouadi M, McGoron AJ, Gulec SA: 18F-FLT positron emission tomography/computed tomography imaging in pancreatic cancer: determination of tumor proliferative activity and comparison with glycolytic activity as measured by 18F-FDG positron emission tomography/computed tomography imaging. Mol Imaging Radionucl Ther 2016;25:32–38.
53Tehrani OS, Shields AF: PET imaging of proliferation with pyrimidines. J Nucl Med 2013;54:903–912.
54Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ, et al: 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med 2013;54:532–540.
55Bollineni VR, Kramer GM, Jansma EP, Liu Y, Oyen WJ: A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer 2016;55:81–97.
56Bussink J, Kaanders JH, Rijken PF, Raleigh JA, van der Kogel AJ: Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res 2000;153:398–404.
W. Woliner-van der Weg, PhD or J. Bussink, MD, PhD
Department of Radiation Oncology, Radboud University Medical Center
P.O. Box 9101
NL–6500 HB Nijmegen (115) (The Netherlands)
E-Mail [email protected] or [email protected]
Конец ознакомительного фрагмента.
Текст предоставлен ООО «ЛитРес».
Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.
Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного
